Vaxxinity, Inc. (VAXX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VAXX Stock Price Chart Interactive Chart >
VAXX Price/Volume Stats
| Current price | $4.50 | 52-week high | $22.77 |
| Prev. close | $4.29 | 52-week low | $3.04 |
| Day low | $4.17 | Volume | 245,700 |
| Day high | $4.67 | Avg. volume | 693,332 |
| 50-day MA | $4.38 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 566.28M |
Vaxxinity, Inc. (VAXX) Company Bio
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Latest VAXX News From Around the Web
Below are the latest news stories about Vaxxinity Inc that investors may wish to consider to help them evaluate VAXX as an investment opportunity.
Vaxxinity says COVID-19 shot had three times stronger antibody response than mRNA shotsVaxxinity (VAXX) shares are trading higher after announcing that the company’s experimental COVID-19 vaccine UB-612 generated an antibody response three times stronger than the… |
Vaxxinity''s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of ConcernInvestigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccines UB-612 elicits >3 times higher titers of neutralizing antibodies against Omicron variant than reported by an approved mRNA vaccine DALLAS, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2... |
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of ConcernInvestigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccinesUB-612 elicits >3 times higher titers of neutralizing antibodies against Omicron variant than reported by an approved mRNA vaccine DALLAS, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, toda |
Volatility in Vaxxinity continues; shares down 7% todayTrading in Vaxxinity has been very volatile over the last week, and today, shares are right around where there were when the stock opened a week ago. |
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease StudyVaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate. |
VAXX Price Returns
| 1-mo | 19.36% |
| 3-mo | -10.36% |
| 6-mo | -67.15% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -19.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...